Along the same lines, it has been demonstrated that total annual cost-savings with insulin analogs is 1590 USD per patient, of which 788 USD is hypoglycemia-related cost-savings and 600 USD is due to other DM-related cost-savings [50]. Here, INS is linked to Hypoglycemia.